Do you continue somatostatin analogs beyond progression to maintain disease control in low-intermediate grade neuroendocrine tumors?

Unfortunately there is no clear data on whether to continue somatostatin analogues (SSA) upon progression in NETs. Certainly for a functional tumor (ie carcinoid syndrome) it makes perfect sense to continue an SSA.

An exception to continuing SSA upon progression is considered when we examine the NETT...